Skip to content

The Lancet

ISSN 0140-6736, 1474-547X

9 papers in the library · 1,740 citations · publishing 1982-2025

Papers

Sort Most recent Most cited

Bipolar disorder.

The Lancet July 22, 2025 Balwinder Singh, Holly A Swartz, Alfredo B. Cuellar Barboza et al. 66 citations

The hallmark of bipolar disorder is hypomania or mania, and the predominant phase of illness is depression. Affecting approximately 40 million individuals worldwide, bipolar disorder is associated with a substantial psychosocial, medical, and financial burden and increased mortality from suicide and other causes. Diagnosis can be challenging due to symptom overlap with attention-deficit...

DOI: 10.1016/S0140-6736(25)01140-7 (opens in new tab) Full text (opens in new tab) Bipolar disorder Mental health treatment Disease etiology Diagnostic challenges

Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial

The Lancet July 4, 2015 Willem Kuyken, Rachel Hayes, B. Barrett et al.

BACKGROUND Individuals with a history of recurrent depression have a high risk of repeated depressive relapse or recurrence. Maintenance antidepressants for at least 2 years is the current recommended treatment, but many individuals are interested in alternatives to medication. Mindfulness-based cognitive therapy (MBCT) has been shown to reduce risk of relapse or recurrence compared with usual...

Drug-induced fibrotic valvular heart disease.

The Lancet August 15, 2009 Sanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis et al.

The initial association between the development of valvular heart disease and drugs stems from observations made during the use of methysergide and ergotamine for migraine prophylaxis in the 1960s. Since then, the appetite suppressants fenfluramine and dexfenfluramine, the dopamine agonists pergolide and cabergoline, and more recently, the recreational drug ecstasy (3,4...

Near-death experience in survivors of cardiac arrest: a prospective study in the Netherlands

The Lancet December 1, 2001 Pirn van Lommel, Ruud van Wees, Vincent Meyers et al. 679 citations

BackgroundSome people report a near-death experience (NDE) after a life-threatening crisis. We aimed to establish the cause of this experience and assess factors that affected its frequency, depth, and content.MethodsIn a prospective study, we included 344 consecutive cardiac patients who were successfully resuscitated after cardiac arrest in ten Dutch hospitals. We compared demographic,...

DOI: 10.1016/s0140-6736(01)07100-8 (opens in new tab) Unconsciousness Cardiopulmonary resuscitation Prospective cohort study Myocardial infarction +3

Dissociation in people who have near-death experiences: out of their bodies or out of their minds?

The Lancet February 1, 2000 Bruce Greyson 149 citations

BackgroundSome people who come close to death report having experiences in which they transcend the boundaries of the ego and the confines of time and space. Such near-death experiences (NDEs) share some features with the phenomenon of dissociation, in which a person's self identity becomes detached from bodily sensation. This study explored the frequency of dissociative symptoms in people who...

Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings

The Lancet October 1, 1998 Ud Mccann, Zsolt Szabó, Ursula Scheffel et al. 664 citations

Quantitative PET studies with a ligand selective for 5-HT transporters can be used to assess the status of 5-HT neurons in the living human brain. We show direct evidence of a decrease in a structural component of brain 5-HT neurons in human MDMA users.

Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy").

The Lancet August 15, 1992 J A Henry, K J Jeffreys, S Dawling

The risk of adverse reactions to 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as "ecstasy", is now widely known in both the USA and UK, but the patterns of illness remain varied. We report our experience during 1990 and 1991. There has been a recent increase in cases of severe toxicity following recreational misuse of small amounts of MDMA. Among 7 fatalities, the pattern of...

Features of "near-death experience" in relation to whether or not patients were near death

The Lancet November 1, 1990 J. Owens, E.W. Cook, I. Stevenson 182 citations

The medical records of 58 patients, most of whom believed they were near death during an illness or after an injury and all of whom later remembered unusual experiences occurring at the time, were examined. 28 patients were judged to have been so close to death that they would have died without medical intervention; the other 30 patients were not in danger of dying although most of them thought...

Cannabis-associated psychosis with hypomanic features.

The Lancet December 18, 1982 D Rottanburg, A H Robins, O Ben-Arie et al.

The mental state of 20 psychotic men with high urinary cannabinoid levels on admission to a psychiatric hospital was compared with that of 20 matched cannabis-free controls. All patients underwent toxicological analysis to exclude the presence of alcohol and other exogenous agents. Cannabis levels were measured by a semiquantitative enzyme immunological technique and mental state was assessed...